Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study in Healthy Volunteers to Evaluate the Bioavailability of Risankizumab New Formulation in Pre-filled Syringe Relative to 90 mg/mL Formulation in Pre-filled Syringe and Characterization of Risankizumab Pharmacokinetics Using New Formulation in Auto-injector

NCT05283681 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05283681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study in Healthy Volunteers to Evaluate the Bioavailability of Risankizumab New Formulation in Pre-filled Syringe Relative to 90 mg/mL Formulation in Pre-filled Syringe and Characterization of Risankizumab Pharmacokinetics Using New Formulation in Auto-injector
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
April 2, 2019
Completion date
November 11, 2019
Enrollment
226 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers